Polish bioinformatics company Intelliseq, specializing in the automated analysis and interpretation of variations in the human genome sequence, has secured €4.5 million in its latest funding round.
The investment was led by Vinci HiTech, managed by Vinci S.A., with participation from Unfold.vc and a group of private investors, including Tadeusz Wesołowski, founder of Prosper S.A. The newly acquired capital will drive the company’s expansion into the US market and accelerate the development of innovative algorithms for disease risk prediction.
NGS and advanced analytics are transforming genomic medicine
Clinical genomics is one of the fastest-growing fields in medicine, transforming the way diseases are diagnosed and treated. Next-generation sequencing (NGS) has unlocked an unprecedented level of insight into the human genome. In a study involving 1,436 patients with diverse clinical presentations, NGS-based testing achieved a diagnostic rate of 46.7%, identifying molecular diagnoses for over 342 distinct disorders.
The global NGS data analysis market was valued at approximately $999.4 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 23.10% from 2025 to 2030. This surge is driven by the increasing adoption of NGS in clinical diagnostics, particularly in oncology, rare diseases, and genetic disorders.
Unlocking the full potential of genomics requires advanced analytical technologies capable of processing vast amounts of genetic data. The focus of Intelliseq is to automate and accelerate genome analysis and interpretation.
Advanced bioinformatics driving precision medicine
Founded in 2014 by four scientists – Klaudia Szklarczyk-Smolana, Marcin Piechota, Michał Korostyński, and Sławomir Gołda – Intelliseq’s flagship platform, iFlow, aims to enable laboratories to flexibly design modular analytical workflows.
„Genomics is still only scratching the surface of its potential. Currently, it is mainly used for diagnosing complex cases and profiling cancer, but its applications go far beyond that. Emerging genomic data banks and advanced analytical algorithms pave the way for precision healthcare, personalized treatments, and better drug compatibility for patients. This is exactly where bioinformatics solutions are headed,” said Klaudia Szklarczyk-Smolana, PhD, CEO of Intelliseq, emphasizes.
The company provides its solutions to research centers and laboratories worldwide. Intelliseq partners with institutions like the US-based Metrodora Institute, an advanced medical center specializing in multi-system disease diagnostics, and DNAnexus, a digital platform for genomic biobanks that powers the world’s largest genomic biobank, UK Biobank.
Strategic investment and US market expansion
The newly secured funding will primarily support Intelliseq’s international expansion, with a strong focus on the US market.
„Our priority is the continued commercialization and global deployment of advanced genome analysis tools. We see a growing demand for scalable bioinformatics solutions, especially in the US,” Szklarczyk-Smolana adds.
It will also enable further validation and implementation of its technology in diagnostic laboratories and the continued development of predictive algorithms.
„This co-investment brings together investors with complementary expertise, providing Intelliseq not only with solid financial backing but also with unique strategic and operational support. Unfold.vc specializes in investments in innovative technologies and scalable business models, as demonstrated by the success of companies like Infermedica and Brand24 from their portfolio,” commented Bartosz Drabikowski, CEO, Vinci S.A.
